Search

Displaying results 9681 - 9690 of 10000 in total
  1. Drug

    9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide

    go.drugbank.com/drugs/DB02842
    Experimental

    9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.

    Synonyms: 9-amino-N-(3-dimethylaminopropyl)acridine-4-carboxamide, 9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
  2. Drug

    Actinium Ac 225 dotatate

    go.drugbank.com/drugs/DB23632
    Investigational

    Actinium Ac 225 dotatate is under investigation in clinical trial NCT07150806 (RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma).

  3. Drug

    AAV8-RK-RetGC

    go.drugbank.com/drugs/DB32389
    Experimental

    AAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.

  4. Drug

    Prostaglandin G2

    go.drugbank.com/drugs/DB03866
    Experimental

    A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]

  5. Drug

    Erythritol

    go.drugbank.com/drugs/DB04481
    Investigational

    Erythritol is a four-carbon sugar that is found in algae, fungi, and lichens. It is twice as sweet as sucrose and can be used as a coronary vasodilator.

  6. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. [L4741] … immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs).

  7. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  8. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

    Categories: Complex Mixtures
  9. Drug

    Contulakin-G

    go.drugbank.com/drugs/DB05950
    Experimental

    Contulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.

  10. Drug

    CRA-028129

    go.drugbank.com/drugs/DB05951
    Experimental

    CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.